Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Abstract Background The majority of patients with hemophilia A with inhibitors who undergo immune tolerance induction (ITI) achieve successful tolerance and transition to factor VIII (FVIII) prophylaxis. A portion of these patients have switched to emicizumab for bleeding prevention. However, the ri...

Full description

Bibliographic Details
Main Authors: Glaivy Batsuli, Amanda Greene, Shannon L. Meeks, Robert F. Sidonio Jr
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
antibodies
factor VIII
hemophilia A
immune tolerance
pediatrics
Online Access:https://doi.org/10.1002/rth2.12475

Similar Items

Similar Items